Terreehorst 2003.
| Methods | Double‐blind randomised controlled trial | |
| Participants | 279 participants aged 8 to 50 years with history of allergic rhinitis and/or asthma | |
| Interventions | Using bed covers that were impermeable to mite allergens | |
| Outcomes | Score on the rhinitis‐specific VAS, daily symptom score, the score on nasal allergen‐provocation testing, and concentrations of Der p1 and Der f1 | |
| Notes | — | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Adequate sequence generation? | Low risk | "Central randomisation was used" |
| Allocation concealment? | Low risk | Adequate |
| Blinding? | Low risk | "A randomised, double‐blind, placebo‐controlled trial" |
| Incomplete outcome data addressed? All outcomes | Low risk | Loss to follow up is described fully in Figure 1. "Intention‐to‐treat analysis was performed with the use of data all 232 patients from whom valid scores on the visual‐analogue scale could be obtained after 12 months" |
| Free of selective reporting? | Low risk | No evidence of selective reporting of outcomes |
| Free of other bias? | Low risk | No evidence of other bias |
HDM = house dust mite PEF = peak expiratory flow RQLQ = rhinoconjunctivitis quality of life questionnaire VAS = visual analogue scale